ADMA Biologics (NASDAQ:ADMA) Raised to Strong-Buy at Canaccord Genuity Group

ADMA Biologics (NASDAQ:ADMA) was upgraded by equities researchers at Canaccord Genuity Group to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Several other research analysts have also recently issued reports on ADMA. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Wall Street Zen cut ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Saturday. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Finally, Mizuho cut their price objective on shares of ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Three equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $25.67.

ADMA Biologics Stock Up 0.4%

ADMA stock traded up $0.04 during mid-day trading on Monday, reaching $10.82. The company had a trading volume of 1,011,674 shares, compared to its average volume of 5,013,423. The firm has a fifty day simple moving average of $13.23 and a 200 day simple moving average of $15.76. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of 18.05 and a beta of 0.82. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same period in the previous year, the company posted $0.46 earnings per share. The business’s revenue for the quarter was up 18.4% on a year-over-year basis. Analysts forecast that ADMA Biologics will post 0.93 earnings per share for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. This represents a 2.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steve Elms bought 7,000 shares of ADMA Biologics stock in a transaction dated Thursday, March 5th. The stock was acquired at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the acquisition, the director directly owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their position. The disclosure for this purchase is available in the SEC filing. 3.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ADMA Biologics

Several large investors have recently modified their holdings of the stock. Salomon & Ludwin LLC acquired a new stake in shares of ADMA Biologics during the third quarter worth $25,000. Rothschild Investment LLC increased its stake in ADMA Biologics by 373.8% in the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,495 shares during the period. Summit Securities Group LLC purchased a new position in ADMA Biologics during the 4th quarter worth $29,000. Clearstead Advisors LLC raised its position in ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after buying an additional 795 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics in the 3rd quarter worth $34,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.